Literature DB >> 23380694

Obesity and the Cardiorenal Metabolic Syndrome: Therapeutic Modalities and Their Efficacy in Improving Cardiovascular and Renal Risk Factors.

Ankur Jindal1, Stephen Brietzke, James R Sowers.   

Abstract

The prevalence of obesity has increased rapidly in the United States. Obesity affects about one third of the adult population and, even though it is attributed to excess calorie intake and inadequate physical activity, its etiopathogenesis is much more complex and is an area of active study. Lifestyle modifications (with a focus on increased activity and decreased calorie intake) have modest efficacy in the treatment of obesity. There is a dearth of safe and effective therapeutic modalities to treat obesity. In this review, we discuss the role of different treatment options in the management of obesity and its comorbidities, with a focus on recently approved drugs and the emerging role of bariatric surgery.

Entities:  

Year:  2012        PMID: 23380694      PMCID: PMC3551409          DOI: 10.1159/000343803

Source DB:  PubMed          Journal:  Cardiorenal Med        ISSN: 1664-5502            Impact factor:   2.041


  66 in total

Review 1.  Medical therapy for the patient with obesity.

Authors:  George A Bray; Donna H Ryan
Journal:  Circulation       Date:  2012-04-03       Impact factor: 29.690

2.  Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects.

Authors:  R R Wing; M D Marcus; R Salata; L H Epstein; S Miaskiewicz; E H Blair
Journal:  Arch Intern Med       Date:  1991-07

Review 3.  Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials.

Authors:  R Padwal; S K Li; D C W Lau
Journal:  Int J Obes Relat Metab Disord       Date:  2003-12

4.  Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.

Authors:  G Derosa; A F G Cicero; A D'Angelo; E Fogari; P Maffioli
Journal:  J Clin Pharm Ther       Date:  2011-08-04       Impact factor: 2.512

5.  Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Frank L Greenway; Ken Fujioka; Raymond A Plodkowski; Sunder Mudaliar; Maria Guttadauria; Janelle Erickson; Dennis D Kim; Eduardo Dunayevich
Journal:  Lancet       Date:  2010-07-29       Impact factor: 79.321

Review 6.  Isolated aerobic exercise and weight loss: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Adrian Thorogood; Salvatore Mottillo; Avi Shimony; Kristian B Filion; Lawrence Joseph; Jacques Genest; Louise Pilote; Paul Poirier; Ernesto L Schiffrin; Mark J Eisenberg
Journal:  Am J Med       Date:  2011-08       Impact factor: 4.965

7.  Body mass index and the risk of development of end-stage renal disease in a screened cohort.

Authors:  Kunitoshi Iseki; Yoshiharu Ikemiya; Kozen Kinjo; Taku Inoue; Chiho Iseki; Shuichi Takishita
Journal:  Kidney Int       Date:  2004-05       Impact factor: 10.612

8.  Effect of moderate diet-induced weight loss and weight regain on cardiovascular structure and function.

Authors:  Lisa de las Fuentes; Alan D Waggoner; B Selma Mohammed; Richard I Stein; Bernard V Miller; Gary D Foster; Holly R Wyatt; Samuel Klein; Victor G Davila-Roman
Journal:  J Am Coll Cardiol       Date:  2009-12-15       Impact factor: 24.094

9.  Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association.

Authors:  John P Bantle; Judith Wylie-Rosett; Ann L Albright; Caroline M Apovian; Nathaniel G Clark; Marion J Franz; Byron J Hoogwerf; Alice H Lichtenstein; Elizabeth Mayer-Davis; Arshag D Mooradian; Madelyn L Wheeler
Journal:  Diabetes Care       Date:  2008-01       Impact factor: 19.112

10.  Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.

Authors:  H B Hubert; M Feinleib; P M McNamara; W P Castelli
Journal:  Circulation       Date:  1983-05       Impact factor: 29.690

View more
  10 in total

Review 1.  Fructose and uric acid: is there a role in endothelial function?

Authors:  Guanghong Jia; Annayya R Aroor; Adam T Whaley-Connell; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2014-06       Impact factor: 5.369

2.  Effect of the FTO rs9930506 Polymorphism on the Main Comorbidities of the Cardiorenal Metabolic Syndrome in an Elderly Spanish Cohort.

Authors:  Eliecer Coto; Beatriz Tavira; Juan Gómez; Salvador Tranche; Carmen Díaz Corte
Journal:  Cardiorenal Med       Date:  2014-04-23       Impact factor: 2.041

Review 3.  Overnutrition, mTOR signaling, and cardiovascular diseases.

Authors:  Guanghong Jia; Annayya R Aroor; Luis A Martinez-Lemus; James R Sowers
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-09-24       Impact factor: 3.619

Review 4.  Estrogen and mitochondria function in cardiorenal metabolic syndrome.

Authors:  Guanghong Jia; Annayya R Aroor; James R Sowers
Journal:  Prog Mol Biol Transl Sci       Date:  2014       Impact factor: 3.622

Review 5.  Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives.

Authors:  Ankur Jindal; Mariana Garcia-Touza; Nidhi Jindal; Adam Whaley-Connell; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-08-01       Impact factor: 4.741

Review 6.  Therapy of obese patients with cardiovascular disease.

Authors:  Ankur Jindal; Adam Whaley-Connell; Stephen Brietzke; James R Sowers
Journal:  Curr Opin Pharmacol       Date:  2013-01-17       Impact factor: 5.547

7.  Obesity-alleviating potential of asiatic acid and its effects on ACC1, UCP2, and CPT1 mRNA expression in high fat diet-induced obese Sprague-Dawley rats.

Authors:  P Rameshreddy; V V Sathibabu Uddandrao; Parim Brahmanaidu; S Vadivukkarasi; Ramavat Ravindarnaik; Pothani Suresh; K Swapna; A Kalaivani; Parimi Parvathi; P Tamilmani; Ganapathy Saravanan
Journal:  Mol Cell Biochem       Date:  2017-10-09       Impact factor: 3.396

Review 8.  Insulin Resistance in Kidney Disease: Is There a Distinct Role Separate from That of Diabetes or Obesity?

Authors:  Adam Whaley-Connell; James R Sowers
Journal:  Cardiorenal Med       Date:  2017-09-30       Impact factor: 2.041

Review 9.  Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence.

Authors:  Kitty Kit Ting Cheung; Andrea On Yan Luk; Wing Yee So; Ronald Ching Wan Ma; Alice Pik Shan Kong; Francis Chun Chung Chow; Juliana Chung Ngor Chan
Journal:  J Diabetes Investig       Date:  2014-11-03       Impact factor: 4.232

10.  Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet.

Authors:  Steven P Vickers; Sharon C Cheetham; Katie R Headland; Keith Dickinson; Rolf Grempler; Eric Mayoux; Michael Mark; Thomas Klein
Journal:  Diabetes Metab Syndr Obes       Date:  2014-07-01       Impact factor: 3.168

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.